Clinical Trial Update: Translocator Protein and Inflammation After Traumatic Brain Injury [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial studying translocator protein as a marker or target in inflammation after traumatic brain injury, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Brain Injury

Snippet

Sponsor: National Institute of Mental Health (NIMH) | Conditions: Traumatic Brain Injury (TBI), Healthy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-07-30